IP Library Granted Patent US 7,964,573
Granted Patent B2
US 7,964,573 · App. 11/814,038 · Granted Jun 21, 2011

Regulating expression of transient receptor potential channel genes

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,964,573
App. No.
11/814,038
Granted
Jun 21, 2011
Kind
B2
Abstract

The present invention relates to compositions related to a polynucleotide encoding a transient receptor potential channel gene. Also disclosed is the use of this polynucleotide, its homologs, fragments, variants and its resultant polypeptides in the diagnosis, prevention and treatment of disease, particularly idiopathic pulmonary arterial hypertension (IPAH). This invention also teaches the use of these polynucleotides and polypeptides as assays for drug discovery and therapies.

Claims (13)

1. A method of treating IPAH in a subject, the method comprising:

a) determining if the subject has a C-254G TRPC6 SNP comprising a G in position −254; and

b) administering to the subject a therapeutically effective amount of a compound that reduces a biological activity of TRPC6 if the subject has the SNP.

2. A method according to claim 1 , wherein the subject is a human.

3. A method according to claim 1 , wherein the compound that reduces a biological activity of TRPC6 is selected from the group consisting of an siRNA, an antisense nucleic acid, a ribozyme, an antibody, a polypeptide fragment, and a peptidomimetic.

4. A method according to claim 1 , wherein compound that reduces a biological activity of TRPC6 is selected from the group consisting of a compound that reduces amount of mRNA encoding TRPC6 polypeptide, and a compound that reduces amount of TRPC6 polypeptide.

5. A method according to claim 4 , wherein the TRPC6 inhibitor is a compound that reduces amount of mRNA encoding TRPC6.

6. A method according to claim 5 , wherein the TRPC6 inhibitor is an siRNA to TRPC6 mRNA.

7. A method according to claim 6 , wherein the siRNA is a double stranded siRNA comprising an RNA sequence corresponding to SEQ ID NO: 4 and the complement thereof.

8. A method according to claim 6 , wherein the double stranded RNA comprises an RNA sequence corresponding to SEQ ID NO: 5 and the complement thereof.

9. A method according to claim 5 , wherein the compound that reduces amount of mRNA encoding TRPC6 comprises an expression vector comprising SEQ ID NO: 5, wherein the expression vector comprises an expression cassette that may be induced to transcribe SEQ ID NO: 5.

10. A method according to claim 4 , wherein the compound that reduces amount of TRPC6 polypeptide is a TRPC6 antibody or a fragment thereof.

11. A method according to claim 10 , wherein the antibody is a monoclonal antibody.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 5, 2011
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026705/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2007
From: REMILLARD, CARMELLE; RUBIN, LEWIS J.; YU, YING; YUAN, JASON X.-J.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 019932/0957 →
Continuity (3)
Provisional Application 60643809 · Jan 14, 2005
Provisional Application 60643806 · Jan 15, 2005
Related Publication 20080118497A1 · May 22, 2008